RxDoctor Payments DataLook up a doctor →

Samuel Shinkle, PA

Physician Assistant · Meridian, IDNPI 1558735514

Payments from drug & device makers

$10,483in general payments, 2019–2025

Across 457 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Pfizer$903
  • AbbVie$726
  • AstraZeneca$655
  • Lilly USA, LLC$591
  • Novo Nordisk$495
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$10,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,483 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$54,489
Medicare patients
102
Services billed
1,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$55,527
EliquisApixaban58$55,301
JardianceEmpagliflozin29$46,564
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,804
LinzessLinaclotide25$20,355
XareltoRivaroxaban11$17,482
MounjaroTirzepatide16$16,421
TrintellixVortioxetine Hydrobromide12$14,098
QuliptaAtogepant11$11,379
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,722
VascepaIcosapent Ethyl13$5,294
SymbicortBudesonide/Formoterol Fumarate14$3,430
Levothyroxine Sodium125$1,731
Atorvastatin Calcium157$1,660
Albuterol Sulfate HfaAlbuterol Sulfate70$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$495$55,52745 claims
PfizerEliquis$903$55,30158 claims
Boehringer IngelheimJardiance$380$46,56429 claims
AbbVieLinzess, Qulipta$726$31,73436 claims
GSKTrelegy Ellipta$478$20,80424 claims
Johnson & JohnsonXarelto$99$17,48211 claims
Lilly USA, LLCMounjaro$591$16,42116 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$49$14,09812 claims
AstraZenecaSymbicort$655$3,43014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →